Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 286

1.

Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.

Jankelevich S, Mueller BU, Mackall CL, Smith S, Zwerski S, Wood LV, Zeichner SL, Serchuck L, Steinberg SM, Nelson RP, Sleasman JW, Nguyen BY, Pizzo PA, Yarchoan R.

J Infect Dis. 2001 Apr 1;183(7):1116-20. Epub 2001 Mar 1.

PMID:
11237839
[PubMed - indexed for MEDLINE]
Free Article
2.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
[PubMed - indexed for MEDLINE]
3.

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.

PMID:
11730396
[PubMed - indexed for MEDLINE]
4.

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.

Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA.

N Engl J Med. 1997 Sep 11;337(11):734-9.

PMID:
9287228
[PubMed - indexed for MEDLINE]
Free Article
5.

Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus.

Wintergerst U, Hoffmann F, Sölder B, Notheis G, Petropoulou T, Eberle J, Gürtler L, Belohradsky BH.

Pediatr Infect Dis J. 1998 Jun;17(6):495-9.

PMID:
9655541
[PubMed - indexed for MEDLINE]
6.

Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections.

van Rossum AM, Niesters HG, Geelen SP, Scherpbier HJ, Hartwig NG, Weemaes CM, Veerman AJ, Suur MH, de Graeff-Meeder ER, Slieker WA, Hop WC, Osterhaus AD, Burger DM, De Groot R.

J Pediatr. 2000 Jun;136(6):780-8.

PMID:
10839877
[PubMed - indexed for MEDLINE]
7.

Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.

Gray CM, Schapiro JM, Winters MA, Merigan TC.

AIDS Res Hum Retroviruses. 1998 May 1;14(7):561-9.

PMID:
9591710
[PubMed - indexed for MEDLINE]
8.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.

PMID:
11064501
[PubMed - indexed for MEDLINE]
9.

Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells.

Evans TG, Bonnez W, Soucier HR, Fitzgerald T, Gibbons DC, Reichman RC.

Antiviral Res. 1998 Oct;39(3):163-73.

PMID:
9833957
[PubMed - indexed for MEDLINE]
10.

A phase I/II study of the protease inhibitor indinavir in children with HIV infection.

Mueller BU, Sleasman J, Nelson RP Jr, Smith S, Deutsch PJ, Ju W, Steinberg SM, Balis FM, Jarosinski PF, Brouwers P, Mistry G, Winchell G, Zwerski S, Sei S, Wood LV, Zeichner S, Pizzo PA.

Pediatrics. 1998 Jul;102(1 Pt 1):101-9.

PMID:
9651421
[PubMed - indexed for MEDLINE]
11.
12.

Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume.

Vigano A, Vella S, Saresella M, Vanzulli A, Bricalli D, Di Fabio S, Ferrante P, Andreotti M, Pirillo M, Dally LG, Clerici M, Principi N.

AIDS. 2000 Feb 18;14(3):251-61.

PMID:
10716501
[PubMed - indexed for MEDLINE]
13.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA, Fischl MA.

N Engl J Med. 1997 Sep 11;337(11):725-33.

PMID:
9287227
[PubMed - indexed for MEDLINE]
Free Article
14.

A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.

Mole L, Schmidgall D, Holodniy M.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):260-5.

PMID:
11464145
[PubMed - indexed for MEDLINE]
15.

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.

Pialoux G, Raffi F, Brun-Vezinet F, Meiffrédy V, Flandre P, Gastaut JA, Dellamonica P, Yeni P, Delfraissy JF, Aboulker JP.

N Engl J Med. 1998 Oct 29;339(18):1269-76.

PMID:
9791142
[PubMed - indexed for MEDLINE]
Free Article
16.

Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease.

Piketty C, Castiel P, Belec L, Batisse D, Si Mohamed A, Gilquin J, Gonzalez-Canali G, Jayle D, Karmochkine M, Weiss L, Aboulker JP, Kazatchkine MD.

AIDS. 1998 May 7;12(7):745-50.

PMID:
9619806
[PubMed - indexed for MEDLINE]
17.

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.

Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F; NOVAVIR (ANRS 073) Study Group.

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. Erratum in: J Acquir Immune Defic Syndr. 2003 Jan;32(1):116..

PMID:
12473833
[PubMed - indexed for MEDLINE]
18.

Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.

Ioannidis JP, Havlir DV, Tebas P, Hirsch MS, Collier AC, Richman DD.

AIDS. 2000 Jul 28;14(11):1481-8.

PMID:
10983634
[PubMed - indexed for MEDLINE]
19.

Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.

Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis JP, Holohan MK, Leavitt R, Boone G, Richman DD.

N Engl J Med. 1998 Oct 29;339(18):1261-8.

PMID:
9791141
[PubMed - indexed for MEDLINE]
Free Article
20.

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.

Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, Valentine FT, McMahon D, Gonzalez C, Jonas L, Emini EA, Chodakewitz JA, Isaacs R, Richman DD.

Ann Intern Med. 2000 Jul 4;133(1):35-9.

PMID:
10877738
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk